Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Christine A. Strick"'
Autor:
Steve S. Gernhardt, Kathryn A. Welch, Jennifer L. Liras, Cheryl Li, Michelle A. Salafia, Haojing Rong, Cheng Chang, Patrick Robert Verhoest, Kari R. Fonseca, Tristan S. Maurer, Christine A. Strick, Laura E. Zawadzke, Jamison B. Tuttle, Brian M. Campbell, Aarti Sawant-Basak, Weldon Horner, Amy B. Dounay
Publikováno v:
Molecular pharmacology. 94(2)
Kynurenic acid (KYNA) plays a significant role in maintaining normal brain function, and abnormalities in KYNA levels have been associated with various central nervous system disorders. Confirmation of its causality in human diseases requires safe an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebf47151ea884653446a1868b8f4bbe1
https://pubmed.ncbi.nlm.nih.gov/29853495
https://pubmed.ncbi.nlm.nih.gov/29853495
Autor:
Amy B. Dounay, Kari R. Fonseca, Graham V. Williams, Christine A. Strick, Douglas S. Chapin, Mihály Hajós, Amanda L. Abbott, Damon Young, William E. Hoffmann, Dina McGinnis, Weldon Horner, Tamás Kiss, Brooke M. Roberts, Rouba Kozak, Victor Guanowsky, Patricia A. Seymour, Brian M. Campbell, Stacy A. Castner
Publikováno v:
Journal of Neuroscience. 34:10592-10602
The elevation of kynurenic acid (KYNA) observed in schizophrenic patients may contribute to core symptoms arising from glutamate hypofunction, including cognitive impairments. Although increased KYNA levels reduce excitatory neurotransmission, KYNA h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a6047a2dd863fcfb3f794b280e2b69
https://doi.org/10.1523/jneurosci.1107-14.2014
https://doi.org/10.1523/jneurosci.1107-14.2014
Autor:
Christine P. Diggle, Nicholas J. Brandon, Khanh Q. Nguyen, Eamonn Sheridan, Manju A. Kurian, Joanne Ng, Veronica Reinhart, Michelle Vanase-Frawley, Melanie Allen, Saghira Malik Sharif, Christine A. Strick, Marius Politis, Eija Anttila, Tiago Reis Marques, Stacey J. Sukoff Rizzo, Alexander F. Markham, Karen Pysden, Erik I. Charych, Christopher M. Watson, Larry C. James, Laura Huilaja, Ian M. Carr, Jan-Philip Schülke, Christopher J. Schmidt, Juha O. Rinne, Kaisa Tasanen, Matti Kallioinen, Kati Alakurtti, Katariina Mankinen, Raija Sormunen, Somayyeh Fahiminiya, John F. Harms, Reetta Hinttala, Johanna Uusimaa, Oliver D. Howes, Päivi Vieira, Hannaleena Kokkonen, Jacek Majewski, Jarkko Johansson, Tiina Hurskainen, David T. Bonthron, Michael Popiolek
Deficits in the basal ganglia pathways modulating cortical motor activity underlie both Parkinson disease (PD) and Huntington disease (HD). Phosphodiesterase 10A (PDE10A) is enriched in the striatum, and animal data suggest that it is a key regulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b9408060ac2d9056541d39ae6f095b9
https://europepmc.org/articles/PMC4833436/
https://europepmc.org/articles/PMC4833436/
Autor:
Brian Rago, Vinod D. Parikh, Bruce M. Bechle, Somraj Ghosh, Edelweiss Evrard, Brian M. Campbell, Christine A. Strick, Jamison B. Tuttle, Xinmin Gan, Amy B. Dounay, Kari R. Fonseca, Laura E. Zawadzke, Larry C. James, Jayvardhan Pandit, Michelle A. Salafia, Ji-Young Kim, Laura A. McAllister, Patrick Robert Verhoest, Weldon Horner, Cheng Chang, Marie Anderson
Publikováno v:
ACS Medicinal Chemistry Letters. 4:37-40
A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a92127bdf5d5f958d781a03a20a82086
https://doi.org/10.1021/ml300237v
https://doi.org/10.1021/ml300237v
Autor:
Akira Sawa, Barbara S. Slusher, Hanna Jaaro-Peled, Ying Wu, Sandra J. Engle, Camilo Rojas, Christine A. Strick, Nicholas J. Brandon, Takashi Tsukamoto, Krystyna M. Wozniak, Ajit G. Thomas, Rana Rais
Publikováno v:
Drug Metabolism and Disposition. 40:2067-2073
D-Amino acid oxidase (DAAO) catalyzes the oxidative deamination of D-amino acids including D-serine, a full agonist at the glycine modulatory site of the N-methyl-d-aspartate (NMDA) receptor. To evaluate the significance of DAAO-mediated metabolism i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c741e648edaca23811b2ae8628f7b03
https://doi.org/10.1124/dmd.112.046482
https://doi.org/10.1124/dmd.112.046482
Autor:
Kari R. Fonseca, Rong Suobao, Bruce M. Bechle, Xinmin Gan, Michelle Marie Claffey, Amy B. Dounay, Jayvardhan Pandit, Edelweiss Evrard, Jamison B. Tuttle, Laura E. Zawadzke, Christine A. Strick, Brian M. Campbell, Katherine Schuyten, Artem G. Evdokimov, Vinod D. Parikh, Marie Anderson, Somraj Ghosh, Matthew R. Reese, James J. Valentine, Hong Wang, Patrick Robert Verhoest, Weldon Horner, Ji-Young Kim, Vanessa Paradis, Laura A. McAllister, Matthew Merrill Hayward, Michelle A. Salafia
Publikováno v:
ACS Medicinal Chemistry Letters. 3:187-192
Kynurenine aminotransferase (KAT) II has been identified as a potential new target for the treatment of cognitive impairment associated with schizophrenia and other psychiatric disorders. Following a high-throughput screen, cyclic hydroxamic acid PF-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dcbfbd5f6721faf10267dd4dae396be
https://doi.org/10.1021/ml200204m
https://doi.org/10.1021/ml200204m
Autor:
Mary Piotrowski, Allen J. Duplantier, Christine A. Strick, Brian D. Harvey, Mark J. Majchrzak, Cheryl Li, Patricia A. Seymour, Christopher J. Schmidt, Carol B. Fox, Alan H. Ganong, Larry C. James, F. David Tingley, Andres D. Ramirez, James T. Downs, Mihály Hajós, Victor Guanowsky, Liam Scott, Stacey L. Becker, Youfen Xu, Stefanus J. Steyn, Ayman El-Kattan, Brian Rago
Publikováno v:
Neuropharmacology. 61:1001-1015
Observations that N-Methyl-D-Aspartate (NMDA) antagonists produce symptoms in humans that are similar to those seen in schizophrenia have led to the current hypothesis that schizophrenia might result from NMDA receptor hypofunction. Inhibition of D-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d50eb849564a55d05e9986564219f8
https://doi.org/10.1016/j.neuropharm.2011.06.029
https://doi.org/10.1016/j.neuropharm.2011.06.029
Autor:
Christine A. Strick, Frank S. Menniti, Carol B. Fox, Larry C. James, Christopher J. Schmidt, Seeger Thomas Francis
Publikováno v:
Neuropharmacology. 58:444-451
PDE10A is a member of the phosphodiesterase superfamily highly enriched within medium spiny neurons (MSN) in mammalian striatum. We have used inhibitors of PDE10A and quantitative measures of mRNA to demonstrate that PDE10A controls striatal gene exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3701294c30456811f01c658ea8a3ec1a
https://doi.org/10.1016/j.neuropharm.2009.09.008
https://doi.org/10.1016/j.neuropharm.2009.09.008
Autor:
Christine A. Strick, Judith A. Siuciak
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 3:527-532
Phosphodiesterase 10A (PDE10A) is a recently identified cyclic nucleotide phosphodiesterase expressed primarily in dopaminoreceptive medium spiny neurons of the striatum. This article provides a brief overview of the characterization, localization an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::419a704800bca725aa2efadd374cf366
https://doi.org/10.1016/j.ddstr.2006.10.012
https://doi.org/10.1016/j.ddstr.2006.10.012
Autor:
Douglas S. Chapin, Sheryl A. McCarthy, Jeffrey L. Stock, Christopher J. Schmidt, Robert D. Williams, Christine A. Strick, Frank S. Menniti, Larry C. James, John D. McNeish, Remie A. Fujiwara, Judith A. Siuciak
Publikováno v:
Neuropharmacology. 51:374-385
PDE10A is a newly identified phosphodiesterase that is highly expressed by the medium spiny projection neurons of the striatum. In order to investigate the physiological role of PDE10A in the central nervous system, PDE10A knockout mice (PDE10A(-/-))
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9e7278d66bd5af1074094a2e589f0c6
https://doi.org/10.1016/j.neuropharm.2006.01.012
https://doi.org/10.1016/j.neuropharm.2006.01.012